Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06473779 · ClinicalTrials.gov registry record · Phase 3
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
A Phase 3 study of Severe Asthma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 326
- Enrollment target
- 20
- Study locations
NCT06473779: Active Phase 3 study of Severe Asthma, sponsored by AstraZeneca.
NCT06473779 is a Phase 3 study of Severe Asthma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 326 participants, below the 3,819-participant average among 9 other Severe Asthma trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06473779, a Phase 3 study of Severe Asthma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 326 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.. Study details include: 1. The study duration will be up to 72 weeks. 2. The treatment duration will be up to 68 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).
Primary Outcome
Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase to either: Outside of the US: * Medium-dose maintenance and reliever therapy, or * Low-dose maintenance and reliever therapy, or * SYMBICORT® anti-inflammatory reliever only In the US: * Medium-dose SYMBICORT® and AIRSUPRA®,or * Low-dose SYMBICORT® and AIRSUPRA®, or * AIRSUPRA® only
Conditions Studied
Interventions
- COMBINATION_PRODUCT Tezepelumab
- COMBINATION_PRODUCT Budesonide/formoterol
- COMBINATION_PRODUCT Albuterol/budesonide (AIRSUPRA®)
- COMBINATION_PRODUCT Mannitol
- COMBINATION_PRODUCT Salbutamol
Study Locations (20)
Other
- Research Site - Berazategui
- Research Site - CABA
- Research Site - Concepción del Uruguay
- Research Site - Mendoza
- Research Site - Mendoza
- Research Site - Quilmes
- Research Site - Rosario
- Research Site - Rosario
- Research Site - San Miguel de Tucumán
- Research Site - Santa Fe
- Research Site - Anderlecht
- Research Site - Edegem
California
- Research Site - Palmdale
Colorado
- Research Site - Colorado Springs
Florida
- Research Site - Miami
Massachusetts
- Research Site - Boston
Missouri
- Research Site - St Louis
New Jersey
- Research Site - New Brunswick
Oklahoma
- Research Site - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2027-06-25 |
| Phase | Phase 3 |
What the registry record for NCT06473779 still lists
NCT06473779 is an interventional study that assigns participants to a tested intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap, below the 3,819-participant average among 9 other Severe Asthma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Severe Asthma appearing as the primary indexed condition, and to 5 interventions - of which Tezepelumab is the first listed.
NCT06473779 names 20 study sites across 9 states, led by Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06473779 about?
NCT06473779 is a clinical study titled "Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.". The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.. Study details include: 1. The study duration will be up to 72 weeks. 2. T...
What is the current status of trial NCT06473779?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2024-09-30. Estimated completion is 2027-06-25.
What conditions does trial NCT06473779 study?
This clinical trial studies the following conditions: Severe Asthma.
What interventions are being tested in trial NCT06473779?
The interventions under investigation include: Tezepelumab (COMBINATION_PRODUCT), Budesonide/formoterol (COMBINATION_PRODUCT), Albuterol/budesonide (AIRSUPRA®) (COMBINATION_PRODUCT), Mannitol (COMBINATION_PRODUCT), Salbutamol (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06473779?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06473779 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06473779's enrollment target sits among peer trials
326 6th of 9 higher than 4 of 9 other Severe Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
RECRUITING · Phase 3
-
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
RECRUITING · Phase 3
-
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
RECRUITING
-
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
RECRUITING · Phase 2
-
Phenotyping Asthma for Bronchial Thermoplasty
RECRUITING
-
Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06410144 · 326 participants · NA
Chronic Kidney Disease-Education (CKD-EDU)
- NCT06586619 · 326 participants · NA
A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV
- NCT07040566 · 326 participants · Phase 2
A Trial of Varenicline for E-cigarette Cessation
- NCT07165860 · 326 participants · NA
Clinical Trial to Reduce Perinatal Intimate Partner Violence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI